Arecor Therapeutics (LON:AREC) Trading 1.9% Higher – Time to Buy?

Arecor Therapeutics plc (LON:AREC) rose 1.9% during mid-day trading on Thursday . The company traded as high as GBX 63.50 and last traded at GBX 63.20. 22,900 shares traded hands during mid-day trading, an increase of 8% from the average daily volume of 21,119 shares. The stock had previously closed at GBX 62.

Arecor Therapeutics Stock Up 2.3%

The company’s 50 day moving average price is GBX 65.15 and its 200 day moving average price is GBX 71.47. The company has a quick ratio of 6.24, a current ratio of 4.35 and a debt-to-equity ratio of 1.52. The firm has a market capitalization of £24.52 million, a price-to-earnings ratio of 32.47 and a beta of -0.18.

Arecor Therapeutics (LON:AREC) last released its earnings results on Monday, April 13th. The company reported GBX 2 earnings per share (EPS) for the quarter. The firm had revenue of GBX 171 million for the quarter. Arecor Therapeutics had a return on equity of 14.26% and a net margin of 38.74%. As a group, research analysts forecast that Arecor Therapeutics plc will post -0.35 earnings per share for the current fiscal year.

About Arecor Therapeutics

Arecor Therapeutics plc (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases.

Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system.